ACLX

NEUTRALM&A

Arcellx, Inc.

2026-04-27

Price

$115.07

+0.03%

Score17.0Priority

Signals6/8 DNA2/13 Act · 2/4 Risk

SentimentNEUTRALScore: 0

Volume9.1xvs 20d avg

Analysis

Arcellx's price action is entirely dictated by its pending $7.8 billion acquisition by Gilead Sciences for $115 per share in cash plus a $5 Contingent Value Right (CVR). The stock's near-zero realized volatility (0.9%) and massive 9.1x volume spike perfectly align with institutional merger arbitrage as Gilead's extended tender offer deadline hits today, April 27, 2026. While the broader RISK_ON macro regime and exceptionally tight credit spreads (0.80%) provide high conviction that Gilead will face no financing or systemic hurdles, ACLX has completely decoupled from market beta. It is now trading as a pure M&A completion play, with the current $115.07 price reflecting the guaranteed cash takeout and a fractional premium for the CVR.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKQUIET ACCUMULATIONINSIDE OUTWEAK FINISHCHURNING

Key Takeaways

Actionable Thesis: ACLX is a pure merger arbitrage play pinned to Gilead's $115 cash offer, offering zero traditional market beta and generating technical signals like QUIET_STORM due to deal anchoring.
Key Risk: A failure to secure the required majority of tendered shares by today's deadline could delay closing and temporarily pressure the $114.72 floor.
What to Watch: The official results of the April 27 tender offer and updates on the December 2026 FDA PDUFA date for anito-cel, which is required to unlock the $5 CVR.

← Back to 2026-04-27 View Full ACLX History →Yahoo Finance &nearr;